Point Biopharma

Eli Lilly concludes POINT Biopharma acquisition for $1.4bn
Pharmaceutical Business Review
Sun, 12/31/23 - 11:40 am
Eli Lilly
Point Biopharma
M&A
radiopharmaceuticals
Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street
BioSpace
Mon, 12/18/23 - 10:14 pm
Point Biopharma
Lantheus Holdings
radioligands
prostate cancer
Eli Lilly
Eli Lilly’s latest $1.4 billion deal might come unglued
Stat
Thu, 12/7/23 - 11:15 pm
Eli Lilly
Point Biopharma
M&A
Lilly Deepens Oncology Pipeline with $1.4B Point Biopharma Purchase
BioSpace
Tue, 10/3/23 - 11:59 am
Eli Lilly
oncology
M&A
Point Biopharma
radioligand
Point looks to turn the tables on Novartis
EP Vantage
Wed, 04/26/23 - 09:55 am
Novartis
Point Biopharma
radiopharmaceuticals
Lantheus has three shots on goal to challenge Novartis
EP Vantage
Wed, 11/16/22 - 10:19 am
Lantheus Medical
Novartis
Point Biopharma
Pluvicto
Luthathera
Aiming at mainstream markets, radiopharmaceutical partners engineer $260M cash deal
Endpoints
Mon, 11/14/22 - 10:42 am
Point Biopharma
radiopharmaceuticals
Just months after SPAC reverse merger, Point Biopharma ups the ante at Indianapolis manufacturing site
Endpoints
Fri, 06/4/21 - 10:38 am
Point Biopharma
SPAC
drug manufacturing
radioligand